| |
|
|
|
Oxford Global, Maritim proArte Hotel, Berlin, Germany
11th - 12th June 2019
Over 18 presentations and case studies focusing on the latest trends and technologies in Bispecifics discovery as well as the considerations for immunogenicity, safety, CMC, biomarkers in bringing Bispecific in clinic. The congress also explores the role of Bispecific antibodies in paving the next wave of biotherapeutics. View agenda: https://bit.ly/2VW3c1X
|
|
|
|
|
|
|
|
Organized by:
|
|
Oxford Global |
|
|
Invited Speakers:
|
|
2019 Bispecific Congress Confirmed Speakers Include: - John Delaney, Executive Director, Research, Amgen
- Antonio de Fougerolles, CEO, Evox Therapeutics
- Christophe Blanchetot, Director Discovery, Argenx BVBA
- Mark Throsby, CSO, Merus
For the full list of confirmed speakers, please see the agenda: https://bit.ly/2VW3c1X
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
https://bit.ly/2W9POra
|
|
|
E-mail:
|
|
g.alonso@oxfordglobal.co.uk
|
|
|
|
|
|
|
|
|